COMPARE: Pharmacokinetic profiles of subcutaneous peginterferon beta‐1a and subcutaneous interferon beta‐1a over 2 weeks in healthy subjects

AIM: Subcutaneous (s.c.) peginterferon beta‐1a injected once every 2 weeks and s.c. interferon beta‐1a injected three times per week (Rebif®) have demonstrated efficacy in relapsing–remitting multiple sclerosis, but direct comparisons of pharmacological activity and tolerability between the two prod...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Xiao, Shang, Shulian, Nestorov, Ivan, Hasan, Jawad, Seddighzadeh, Ali, Dawson, Katherine, Sperling, Bjørn, Werneburg, Brian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Pharmacokinetics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4972154/
https://www.ncbi.nlm.nih.gov/pubmed/27060836
http://dx.doi.org/10.1111/bcp.12968

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4972154/
https://www.ncbi.nlm.nih.gov/pubmed/27060836
http://dx.doi.org/10.1111/bcp.12968

Ejemplares similares